Reviva Pharmaceuticals Holdings, Inc. (RVPH): Operating Income
-$20.20M
Year ended 2025-12-31
-$13.48M
Trailing 12 months to 2026-06-30
| Period ended | Operating Income | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$20.20M | n/m | 2026-03-30, From 2025-01-01 |
| 2024-12-31 | -$30.80M | n/m | 2026-03-30, From 2024-01-01 |
| 2023-12-31 | -$39.50M | n/m | 2025-04-03, From 2023-01-01 |
| 2022-12-31 | -$28.23M | n/c | 2024-04-15, From 2022-01-01 |
| 2021-12-31 | -$10.10M | n/m | 2023-03-30, From 2021-01-01 |
| 2020-12-31 | -$2.43M | n/m | 2022-03-15, From 2020-01-01 |
| 2019-12-31 | -$376.9K | n/a | 2021-05-07, From 2019-01-01 |
Operating Income at similar companies
| Company | Year ended | Operating Income | Change YoY |
|---|---|---|---|
| Reviva Pharmaceuticals Holdings, Inc. (RVPH) | 2025-12-31 | -$20.20M | n/m |
| Aprea Therapeutics, Inc. (APRE) | 2025-12-31 | -$13.23M | n/m |
| Anixa Biosciences Inc (ANIX) | 2025-10-31 | -$11.70M | n/m |
| Synlogic, Inc. (SYBX) | 2025-12-31 | -$4.01M | n/m |
| Aditxt, Inc. (ADTX) | 2025-12-31 | -$19.57M | n/m |
| Cingulate Inc. (CING) | 2025-12-31 | -$19.94M | n/m |
| Cellectar Biosciences, Inc. (CLRB) | 2025-12-31 | -$22.98M | n/m |
| Tempest Therapeutics, Inc. (TPST) | 2025-12-31 | -$26.57M | n/m |
| Lipocine Inc. (LPCN) | 2025-12-31 | -$10.37M | n/m |
Compare RVPH, APRE, ANIX, SYBX side by side · Screen every company in Pharmaceutical Preparations ↗